Retatrutide: research overview

The short version

Retatrutide (LY3437943) is a single-molecule agonist at three metabolic receptors at once: GIP, GLP-1, and glucagon. Semaglutide hits one; tirzepatide hits two; retatrutide hits all three. The glucagon receptor arm adds something the others lack — increased energy expenditure through thermogenic mechanisms — on top of the appetite suppression and glucose effects from the incretin receptors.

Phase 2 trials found mean body-weight reductions of approximately -24% at 48 weeks in adults with obesity ^[15], and -82% relative reduction in liver fat in people with metabolic liver disease ^[14]. Those are the largest numbers in this drug class to date. Retatrutide is important to situate correctly: it is investigational, it is not approved by the FDA or any regulator as of mid-2026, it is in Phase 3 trials, and it is not available as a prescription or consumer product. This page summarizes published Phase 2 evidence and does not advise on any use.

What it is

Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone, C20 fatty-diacid acylated for albumin binding and extended half-life, enabling once-weekly subcutaneous administration (molecular formula: C221H342N46O68, free acid).

Its classification is triple incretin receptor agonist or GGG tri-agonist (GIP/GLP-1/glucagon). It is sometimes informally called a "triple agonist" and very occasionally mislabeled "GLP-3" in secondary sources — that designation is a misnomer; there is no receptor called GLP-3, and the glucagon receptor in retatrutide's profile is the classical glucagon receptor (GCGR), not a new class. The compound is developed by Eli Lilly and is in the TRIUMPH Phase 3 program ^[12].

How it works

Cryo-EM structural work resolved retatrutide bound to all three receptor complexes at 2.68/3.26/2.84 angstroms ^[13]. Key observations:

• Relative potency: approximately 8.9× more potent at the GIPR than native GIP, 0.3× at GCGR, 0.4× at GLP-1R versus endogenous hormones — a deliberately tuned imbalance ^[13].
• At GLP-1R and GCGR, the extracellular loop 1 (ECL1) of the peptide adopts a rigid alpha-helix; at GIPR it forms a flexible loop — a structural difference with implications for receptor-specific signaling ^[13].

The three receptor arms:

• GLP-1R arm: Glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, central appetite suppression — same as semaglutide.
• GIPR arm: Additional insulinotropic and adipose-tissue effects, likely contributing to the incremental weight loss over GLP-1 agonism alone.
• GCGR arm: Increases energy expenditure via thermogenic mechanisms (cAMP/PKA signaling in adipose tissue and liver), drives hepatic lipid mobilization, and raises resting heart rate — the distinguishing pharmacological feature. The energy-expenditure effect is what the field believes accounts for retatrutide's weight-loss step-change over the dual agonists ^[12].

What the research shows

Phase 2 obesity trial (48 weeks). Once-weekly retatrutide 12 mg produced a mean body-weight change of -24.2% versus -2.1% with placebo in 338 adults with obesity. GI adverse events were dose-related and mostly mild to moderate. A dose-dependent heart-rate increase was observed, peaking around 24 weeks ^[15].

Liver fat in metabolic liver disease (MASLD substudy, 24/48 weeks). In 98 participants with obesity or overweight and MASLD (≥10% liver fat by MRI-PDFF, no type 2 diabetes), retatrutide 12 mg reduced relative liver fat by -82.4% at 24 weeks, with 86% of participants reaching normal liver fat (<5%); reductions sustained to 48 weeks (-86.0%) ^[14].

Type 2 diabetes Phase 2 trial (36 weeks). In 281 adults with type 2 diabetes, retatrutide 12 mg reduced HbA1c by -2.02% at 24 weeks and body weight by -16.94% at 36 weeks versus placebo. Mild-moderate GI adverse events in 35% of participants; no severe hypoglycemia, no deaths ^[16].

Triple-agonist pharmacology review (2025). A 2025 narrative review summarizes retatrutide's Phase 1/2 evidence, characterizing the approximately 24% weight loss as a step-change versus prior incretin therapies and reviewing the GI/heart-rate safety profile and the ongoing Phase 3 TRIUMPH program ^[12].

Structural biology. Cryo-EM confirmed simultaneous triple-receptor engagement and quantified relative receptor potencies ^[13].

Reported effects, cautions & safety

Community-reported effects (anecdotal, not clinical evidence).

Retatrutide community accounts — from research-use forums and aggregated self-report analyses — describe appetite suppression that some characterize as more complete than with prior GLP-1-class compounds: not just reduced hunger but a near-total loss of interest in food. Rapid and noticeable weight reduction is a consistent theme, broadly consistent with the Phase 2 trial results. A distinctive and frequently reported effect is increased body warmth — running warmer, sweating more easily — attributed in community discussion to the glucagon receptor arm's thermogenic activity. Elevated resting heart rate is commonly noticed, particularly in the hours after administration; some describe wearable data showing 5–15 bpm above baseline. Nausea peaks in the first weeks and after dose increases; constipation and sulfur burps recur. Early fatigue — heavy legs, needing extra sleep — is frequently mentioned in the initial weeks. Sleep disturbances appear in a subset. Some describe a mood lift; others report lean-mass concerns. All of the above is anecdotal, self-reported, and unverified; no verified doses accompany these community reports.

Safety cautions from the literature.

• Investigational status and unverified gray-market supply: Retatrutide is not approved anywhere. Material obtained outside clinical trials carries no verified identity, purity, or sterility; independent analyses of similar gray-market peptides have found truncated sequences, racemized amino acids, or entirely different compounds ^[15][12].
• GI adverse events: Nausea affected up to 45% of participants at the highest Phase 2 dose; an 18% discontinuation rate at that dose level was driven largely by GI effects. Without dose-escalation oversight, dehydration and electrolyte imbalance risks are amplified ^[15].
• Heart-rate increase: Dose-dependent mean increases of approximately 5–7 bpm at the highest doses, peaking around 24 weeks. A dedicated cardiovascular outcomes trial is ongoing; long-term arrhythmia and MACE effects are unknown ^[15][12].
• Hypoglycemia with insulin or sulfonylureas: Phase 2 diabetic participants on background insulin required insulin de-escalation; the same risk applies in unmonitored use ^[16].
• Lean-mass loss: A body-composition substudy confirms retatrutide reduces lean mass alongside fat mass; the absolute lean loss is clinically meaningful, particularly for older individuals ^[15].
• Long-term safety unknown: TRIUMPH-1/2/3 and dedicated cardiovascular/kidney outcome trials are ongoing as of mid-2026; no long-term outcomes data exist ^[12].

Where it fits

Retatrutide is the frontier compound on this desk — the largest weight-loss numbers in Phase 2, the most mechanistic complexity, and the least regulatory resolution. Its glucagon receptor arm adds energy expenditure to the incretin toolkit, which may explain the step-change in weight loss, but it also introduces the heart-rate signal that the dual and single agonists do not carry in the same degree. Its investigational status is not a detail — it means there is no approved safety profile, no approved dosing, and no regulated supply chain. The Phase 3 TRIUMPH program is the next evidentiary gate ^[12]. Read alongside semaglutide and tirzepatide to understand the incremental receptor logic. See the comparison page for where it fits on the evidence-maturity spectrum.